ReviewClinical and experimental medicine2026
MicroRNAs as novel therapeutic targets against inflammatory bowel disease through modulation of ferroptosis.
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remodeling mechanisms and intervention strategies of the oral mucosal immune barrier.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory Bowel Disease (IBD), driven by mucosal barrier dysfunction and immune regulation disruption, is characterized by chronic gastrointestinal inflammation and frequent disease relapse. While traditional therapies focus on immune suppression, recent evidence identifies ferroptosis-an iron-dependent form of regulated cell death-as a critical driver of intestinal epithelial injury. Central to this process are microRNAs (miRNAs), which act as post-transcriptional "switches" regulating the three metabolic axes of ferroptosis: antioxidant defense (GPX4, System Xc-), iron trafficking, and lipid peroxidation. This review synthesizes emerging evidence on the miRNA-ferroptosis network in IBD. We highlight how specific dysregulated miRNAs, such as miR-129-5p and the IRF7/miR-375 axis, strip the epithelium of its defenses, promoting lethal lipid peroxidation. Furthermore, we examine the clinical transformation of these insights into novel therapies, including the oral small molecule ABX464 (obefazimod) and bioengineered exosome delivery systems. By moving beyond broad immunosuppression to targeted metabolic reprogramming, miRNA-based interventions offer a promising frontier for overcoming resistance to current biologic therapies and achieving deep mucosal healing in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.